These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12420531)

  • 41. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome.
    Guzmán-Fulgencio M; Micheloud D; Lorente R; Bellón JM; Gomez MI; Gurbindo MD; León JA; Muñoz-Fernández MÁ; Resino S
    J Infect; 2011 Mar; 62(3):240-3. PubMed ID: 21256862
    [No Abstract]   [Full Text] [Related]  

  • 42. [Which antiretroviral strategy to use in adults?].
    Tonnerre P
    Rev Infirm; 2003 Sep; (93):12-6. PubMed ID: 14593983
    [No Abstract]   [Full Text] [Related]  

  • 43. [Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():14-5. PubMed ID: 12043064
    [No Abstract]   [Full Text] [Related]  

  • 44. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Side effects of antiretroviral therapy--skin manifestations].
    Esser S
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():8, 10-1. PubMed ID: 19024907
    [No Abstract]   [Full Text] [Related]  

  • 46. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 47. Common adverse effects of antiretroviral therapy for HIV disease.
    Reust CE
    Am Fam Physician; 2011 Jun; 83(12):1443-51. PubMed ID: 21671545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The experts speak. Metabolic complications associated with HIV infection and antiretroviral therapy. Interview by Vicki Glaser.
    Powderly W
    AIDS Patient Care STDS; 2004 Aug; 18(8):431-5. PubMed ID: 15321014
    [No Abstract]   [Full Text] [Related]  

  • 51. Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy.
    Daskalakis D; Aberg JA
    MedGenMed; 2005 Oct; 7(4):9. PubMed ID: 16614631
    [No Abstract]   [Full Text] [Related]  

  • 52. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
    Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiretroviral therapy-associated diseases are common in the long-term.
    Lanzafame M; Lattuada E; Zoppini G; Vento S
    AIDS Res Hum Retroviruses; 2011 Sep; 27(9):931-2. PubMed ID: 21182461
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment options for lipodystrophy in HIV-positive patients.
    Behrens GM
    Expert Opin Pharmacother; 2008 Jan; 9(1):39-52. PubMed ID: 18076337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The problems faced when assessing the prevalence and incidence of antiretroviral-related toxicities.
    Smith CJ; Sabin CA
    Antivir Ther; 2004 Dec; 9(6):865-78. PubMed ID: 15651745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
    Bonacini M
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S104-8. PubMed ID: 14986282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Lipodystrophic syndromes in HIV-infected patients receiving antiretroviral treatment].
    Simeoni J
    Ann Endocrinol (Paris); 2003 Dec; 64(6):490-1. PubMed ID: 15080164
    [No Abstract]   [Full Text] [Related]  

  • 59. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?
    de Mendoza C; Sanchez-Conde M; Ribera E; Domingo P; Soriano V
    AIDS Rev; 2004; 6(3):169-80. PubMed ID: 15595434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.